A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant

In brief

Primary Objectives * To assess the safety and tolerability of RGLS8429 * To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives * To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) * To characterize the pharmacokinetic (PK) properties of RGLS8429 * To assess the impact of RGLS8429 on renal function

Key facts

Study ID
NCT05521191
Run by
Regulus Therapeutics Inc.
People needed
68
Starts
2022-10-06
Expected to finish
2025-03-27
Last updated by the study team
2025-06-03

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.